Related Experiment Video

Updated: Jul 10, 2026

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
09:17

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Published on: September 16, 2019

Evaluation of HIF-1 inhibitors as anticancer agents

Gregg L Semenza1

  • 1Vascular Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, 733 North Broadway, Suite 671, Baltimore, MD 21205, USA. gsemenza@jhmi.edu

Drug Discovery Today
|October 16, 2007
PubMed

Insights

Hypoxia-inducible factor 1 (HIF-1) is crucial in cancer progression and is a validated therapeutic target. Inhibiting HIF-1 shows promise, but optimal drug combinations for cancer treatment remain a challenge.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Hypoxia-inducible factor 1 (HIF-1) is a key regulator of genes involved in multiple cancer hallmarks.
  • HIF-1 overexpression correlates with increased tumor growth, vascularization, and metastasis in animal models.
  • HIF-1alpha overexpression in biopsy samples serves as a prognostic indicator in various cancers.

Purpose of the Study:

  • To highlight the critical role of HIF-1 in cancer biology.
  • To validate HIF-1 as a therapeutic target for anticancer strategies.
  • To underscore the challenge of determining optimal drug combinations for HIF-1 inhibition in cancer treatment.

Main Methods:

  • Review of literature on HIF-1's role in cancer.
  • Analysis of animal model data regarding HIF-1 function.
  • Examination of immunohistochemical studies linking HIF-1alpha to cancer prognosis.
  • Overview of novel anticancer agents targeting HIF-1.

Main Results:

  • HIF-1 regulates crucial cancer processes like immortalization, stem cell maintenance, metabolic reprogramming, and metastasis.
  • HIF-1 loss-of-function inhibits tumor growth, vascularization, and metastasis.
  • Novel anticancer agents targeting HIF-1 are emerging.

Conclusions:

  • HIF-1 is a validated and significant therapeutic target in oncology.
  • Effective inhibition of HIF-1 is achievable through various molecular mechanisms.
  • Optimizing combination drug therapies for HIF-1 targeting is essential for improving cancer treatment outcomes.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...